前列地尔联合厄贝沙坦治疗早期糖尿病肾病(1)
 |
| 第1页 |
参见附件。
[摘要] 目的：观察前列地尔联合厄贝沙坦治疗早期糖尿病肾病(DN)的临床疗效。方法：收集早期2型糖尿病患者120例，随机分成厄贝沙坦组(40例)、前列地尔组(40例)和联合治疗组(40例)。全部病例进行临床观察2周，分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿微量白蛋白(24 h U-mAlb)治疗前后的变化。结果：治疗2周后，联合治疗组[(155.69±30.56)μg/24 h]降低24 h U-mAlb的作用优于厄贝沙坦组[(224.75±36.42)μg/24 h]和前列地尔组[(219.36±34.75)μg/24 h]，差异有统计学意义(P<0.05)。厄贝沙坦组和前列地尔组比较，差异无统计学意义(P>0.05)。结论：前列地尔与厄贝沙坦联合应用是治疗早期糖尿病肾病的有效方法。
[关键词] 糖尿病肾病；前列地尔；厄贝沙坦；尿微量白蛋白
[中图分类号] R587.2 [文献标识码] A [文章编号] 1673-7210(2012)01(a)-065-02
Alprostadil combined with Irbesartan in the treatment of patients with early diabetic nephropathy
LI Keru
The First Department of Internal Medicine, Yunnan Traffic Center Hospital, Yunnan Province, Kunming 654100, China
[Abstract] Objective: To observe the clinical efficacy of Alprostadil combined with Irbesartan in the treatment of early diabetic nephropathy (DN). Methods: 120 patients with early type 2 diabetes of hospitalization were collected and randomly divided into 3 groups: Irbesartan group (40 cases), Alprostadil group (40 cases), combined therapeutic group (40 cases). All cases were observed for 2 weeks. The changes of serum creatinine (Cr), blood urea nitrogen (BUN), 24 hour urine micro albumin (24 h U-mAlb) before and after the treatment were compared. Results: After treatment for 2 weeks, the treatment of combined therapeutic group [(155.69±30.56) μg/24 h] in decreasing 24 h U-mAlb was better than Irbesartan group [(224.75±36.42) μg/24 h] and Alprostadil group [(219.36±34.75) μg/24 h], the differences were significant (P<0.05). The differences between Irbesartan group and Alprostadil group were no significant (P>0.05). Conclusion: The treatment of Alprostadil combined with Irbesartan in early diabetic nephropathy is an effective way.
[Key words] Diabetic nephropathy; Alprostadil; Irbesartan; Urine micro albumin
糖尿病肾病(diabetic nephropathy，DN)是糖尿病(diabetes，DM)微血管并发症，是导致慢性肾衰竭的主要原因之一。DN治疗的关键在于早期诊断及治疗，DN的早期表现主要是尿微量白蛋白(U-mAlb)的升高，对早期DN U-mAlb的治疗可明显延缓DN进入终末期肾病的时间，DN一旦进展成临床蛋白尿期，肾损害是难以可逆的。有效控制早期DN的进展是目前DM临床的重要课题。前列地尔、厄贝沙坦均是临床常用保护肾脏、降低尿微量白蛋白的有效药物。本研究采用前列地尔联合厄贝沙坦治疗早期DN取得良好的临床疗效 ......
您现在查看是摘要介绍页，详见PDF附件(1497kb)。